Archives


Rate this Article: (2) Votes

  Research Article

Year : 2017 | Volume: 2 | Issue: 4 | Pages: 173-184

FORMULATION AND EVALUATION OF ORAL In-Situ GEL OF GLIMEPIRIDE

Venugopalaiah P1, Syed Moula ali*1, Yerikala Ramesh1, K.Saravanakumar2

* Corresponding author

  • 1Ratnam Institute of Pharmacy, Nellore, Andhra Pradesh, India.

    . 2Sree Vidyanikethan College of Pharmacy, Tirupati, Andhra Pradesh, India.

  17/06/2017

  19/06/2017

  07/07/2017

  10/07/2017

  • Venugopalaiah P1, Syed Moula ali*1, Yerikala Ramesh1, K.Saravanakumar2

    , (2017), FORMULATION AND EVALUATION OF ORAL In-Situ GEL OF GLIMEPIRIDE. International Journal of Pharmacometrics and Integrated Biosciences, 2(4): 173-184. doi: 0

Abstract

The main objective of present study is to formulate and evaluate oral in situ gel of the Glimepiride. The oral in situ gelling formulations were prepared using Sodium alginate, HPMC K15M, Calcium carbonate and Methyl paraben. Glimepiride is an antidiabetic and antiarrhythmia agents of the third generation sulfonyl urea’s derivative family. Glimepiride has half-life 5-8 hours and required dose is 1-6 mg a day. It is used for the treatment of Type-2 Diabetes, which acts to trigger pancreas to make more insulin. This may account for better safety profile of drug. The formulation was studied for FT-IR study to interpret the interaction between Drug-Polymer used. Prepared formulations were evaluated for Clarity, PH measurement, Homogeneity, Spreadability, Viscosity measurement, Drug content, Extrudability and Drug diffusion studies. An In vitro drug release study was compared among the different in situ gelling formulations and F3 released 96.8% of drug at the end of 12th hour and was considered as a best formulation. The release of drug through these in situ gel formulations followed by the different kinetic models shows non-fickian diffusion (n=0.576) which was best explained by peppas kinetic model. The formulation F3 was found to be stable for 3 months in accelerated stability study.

Keywords

Type 2 Diabetes, Glimepiride, Oral in situ gel, In vitro drug release, Drug release kinetics etc.